Filtered By:
Education: Study
Nutrition: Weight Loss
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 403 results found since Jan 2013.
Surgical, metabolic, and prognostic outcomes for Roux-en-Y gastric bypass versus sleeve gastrectomy: a systematic review
Surg Obes Relat Dis. 2021 Jul 7:S1550-7289(21)00318-X. doi: 10.1016/j.soard.2021.06.020. Online ahead of print.ABSTRACTThe purpose of this systematic review was to study 4 different aspects of Roux-en-Y gastric bypass (RYBG) and sleeve gastrectomy (SG). Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are two commonly performed bariatric procedures. This systematic review aims to compare RYGB with SG when it comes to weight changes, and cardiometabolic risk profile. Another aim was to evaluate laparoscopic and robotic techniques for both surgeries. PubMED, Cochrane Library, and JAMA Network were searched for art...
Source: Surgery for Obesity and Related Diseases : official journal of the American Society for Bariatric Surgery - October 13, 2021 Category: Surgery Authors: Evander Meneses Israel Zagales Dino Fanfan Ruth Zagales Mark McKenney Adel Elkbuli Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
wEight chanGes, caRdio-mEtabolic risks and morTality in patients with hyperthyroidism (EGRET): a protocol for a CPRD-HES linked cohort study
Introduction
Hyperthyroidism is a common condition affecting up to 3% of the UK population. Treatment improves symptoms and reduces the risk of atrial fibrillation and stroke that contribute to increased mortality. The most common symptom is weight loss, which is reversed during treatment. However, the weight regain may be excessive, contributing to increased risk of obesity. Current treatment options include antithyroid drugs, radioiodine and thyroidectomy. Whether there are differences in either weight change or the long-term cardiometabolic risk between the three treatments is unclear.
Methods and analysis
The study wi...
Source: BMJ Open - October 1, 2021 Category: General Medicine Authors: Torlinska, B., Hazlehurst, J. M., Nirantharakumar, K., Thomas, G. N., Priestley, J. R., Finnikin, S. J., Saunders, P., Abrams, K. R., Boelaert, K. Tags: Open access, Diabetes and Endocrinology Source Type: research
Why You Shouldn ’t Exercise to Lose Weight
Many of us are lacing up our sneakers and starting (or restarting) exercise regimens in hopes of shedding unwanted pounds. Unquestionably, aiming to be more active is a good thing. But if the main reason is to lose weight, your New Year’s resolution could very well backfire.
For starters, exercise—at least the kind most of us do—is typically ineffective for weight loss. Take walking, for example. A 150-pound person who walks briskly for 30 minutes will burn, on average, around 140 calories. That’s equal to one can of soda—not exactly a great return on your investment of time and effort. It&rsq...
Source: TIME: Health - January 12, 2022 Category: Consumer Health News Authors: Robert J. Davis Tags: Uncategorized Source Type: news
Influence of individualized prevention recommendations after one year on the control of hypertension in 3,868 follow-up participants of the ELITE study
CONCLUSION: 56% of the hypertensive participants succeeded in lowering their blood pressure, whereas there was a significant increase in blood pressure, especially in those who were well controlled with antihypertensives. This underlines the need to further motivate normotensive patients to maintain their normotension. The results show that the combination of individual written education and lifestyle interventions are an effective tool for the public health sector to combat hypertension. In our participants, lifestyle interventions have a significant impact on BP change. It should be noted critically that there are still ...
Source: Central European Journal of Public Health - January 13, 2022 Category: International Medicine & Public Health Authors: Bastian Schrader Joachim Schrader Michael Koziolek Albrecht Els ässer Anna-Maria B ünker Berit Hillmann Bernhard Vaske Hermann Haller Stephan L üders Source Type: research
